Vidalin-D
Generic Name
Cholecalciferol
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| vidalin d injection | ৳ 290.00 | N/A |
Description
Overview of the medicine
Vidalin-D Injection is a preparation of Cholecalciferol (Vitamin D3), used to treat and prevent vitamin D deficiency, especially in severe cases or malabsorption syndromes.
Uses & Indications
Dosage
Adults
For severe deficiency: 200,000 IU to 300,000 IU intramuscularly, repeat after 1-3 months if necessary. For maintenance: 20,000 IU to 40,000 IU monthly or as directed.
Elderly
Similar to adult dosage, but caution with concomitant medications and renal function.
Renal_impairment
Use with caution. Dosage adjustment may be required based on serum calcium and phosphate levels and renal function. Active forms of vitamin D might be preferred.
How to Take
For intramuscular (IM) injection only. Administer slowly and deeply into a large muscle mass.
Mechanism of Action
Cholecalciferol is converted in the liver and kidneys to calcitriol, the active form of Vitamin D. Calcitriol regulates calcium and phosphate homeostasis, promoting their absorption from the gut and reabsorption in the kidneys, and influencing bone mineralization.
Pharmacokinetics
Onset
Several days to weeks for full therapeutic effect.
Excretion
Excreted primarily in bile and feces; a small amount is excreted in urine.
Half life
Approximately 15-30 days for cholecalciferol, but active metabolite calcitriol has a half-life of 4-6 hours.
Absorption
Rapidly absorbed from the site of intramuscular injection.
Metabolism
Metabolized in the liver to 25-hydroxycholecalciferol and then in the kidneys to 1,25-dihydroxycholecalciferol (calcitriol), the active form.
Side Effects
Contraindications
- Hypersensitivity to cholecalciferol or any component of the formulation
- Hypercalcemia
- Vitamin D toxicity
- Hyperphosphatemia
Drug Interactions
Corticosteroids
May reduce the effect of vitamin D.
Cardiac glycosides
Increased risk of arrhythmia due to hypercalcemia.
Thiazide diuretics
May increase risk of hypercalcemia.
Cholestyramine, mineral oil, orlistat
May impair absorption of vitamin D.
Anticonvulsants (e.g., phenytoin, barbiturates)
May increase vitamin D metabolism, reducing its effect.
Storage
Store below 30°C, protected from light and moisture. Do not freeze.
Overdose
Symptoms include hypercalcemia (nausea, vomiting, weakness, polyuria, polydipsia, confusion, renal impairment). Treatment involves discontinuation, hydration, and managing hypercalcemia (e.g., loop diuretics, corticosteroids).
Pregnancy & Lactation
Pregnancy Category C. Use only if potential benefit outweighs risk. Excreted in breast milk, use with caution and monitor infant serum calcium.
Side Effects
Contraindications
- Hypersensitivity to cholecalciferol or any component of the formulation
- Hypercalcemia
- Vitamin D toxicity
- Hyperphosphatemia
Drug Interactions
Corticosteroids
May reduce the effect of vitamin D.
Cardiac glycosides
Increased risk of arrhythmia due to hypercalcemia.
Thiazide diuretics
May increase risk of hypercalcemia.
Cholestyramine, mineral oil, orlistat
May impair absorption of vitamin D.
Anticonvulsants (e.g., phenytoin, barbiturates)
May increase vitamin D metabolism, reducing its effect.
Storage
Store below 30°C, protected from light and moisture. Do not freeze.
Overdose
Symptoms include hypercalcemia (nausea, vomiting, weakness, polyuria, polydipsia, confusion, renal impairment). Treatment involves discontinuation, hydration, and managing hypercalcemia (e.g., loop diuretics, corticosteroids).
Pregnancy & Lactation
Pregnancy Category C. Use only if potential benefit outweighs risk. Excreted in breast milk, use with caution and monitor infant serum calcium.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years from manufacturing date.
Availability
Pharmacies, Hospitals
Approval Status
Approved by DGDA
Patent Status
Generic available
WHO Essential Medicine
YesClinical Trials
Extensive clinical data supports the efficacy and safety of cholecalciferol injections for vitamin D deficiency.
Lab Monitoring
- Serum calcium levels
- Serum phosphate levels
- Serum 25(OH)D levels (to monitor vitamin D status)
- Renal function (creatinine, BUN)
Doctor Notes
- Verify serum 25(OH)D levels before and during treatment.
- Educate patients on symptoms of hypercalcemia.
- Consider active vitamin D forms in severe renal impairment.
Patient Guidelines
- Report any symptoms of hypercalcemia (e.g., unusual tiredness, weakness, nausea, vomiting, constipation, or thirst) to your doctor.
- Do not take additional vitamin D supplements without consulting your doctor.
- Maintain regular follow-up appointments for monitoring.
Missed Dose Advice
Since it's an injection administered by a healthcare professional, contact your doctor for advice on rescheduling the dose if missed.
Driving Precautions
Generally no effect on driving or operating machinery. However, if symptoms of hypercalcemia (e.g., confusion, weakness) occur, avoid such activities.
Lifestyle Advice
- Ensure adequate dietary calcium intake.
- Engage in weight-bearing exercises (if appropriate).
- Consider moderate sun exposure, if advised by a doctor.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.